TrkA alternative splicing: A regulated tumor-promoting switch in human neuroblastoma

Cancer Cell

Volumn 6, Issue 4, 2004, Pages 347-360

  Tacconelli, Antonella ^a   Farina, Antonietta R ^a   Cappabianca, Lucia ^a   DeSantis, Giuseppina ^a   Tessitore, Alessandra ^a   Vetuschi, Antonella ^a   Sferra, Roberta ^a   Rucci, Nadia ^a   Argenti, Beatrice ^b   Screpanti, Isabella ^b   Gulino, Alberto ^b,c   Mackay, Andrew R ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c IRCCS NEUROMED   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NERVE GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN;

ALTERNATIVE RNA SPLICING; ANGIOGENESIS; ARTICLE; CANCER INHIBITION; CELL ACTIVITY; CELL SURVIVAL; ENZYME ACTIVITY; EXON; GENE DELETION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC VARIABILITY; HUMAN; NERVE CELL GROWTH; NEURAL CREST; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; STEM CELL; TUMOR GROWTH; TUMOR PROMOTION; TUMOR SUPPRESSOR GENE; XENOGRAFT;

EID: 5444258188     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2004.09.011     Document Type: Article

References (70)

1. Arevalo J.C., Conde B., Hempstead B.L., Chao M.V., Matrin-Zanca D., Perez P. TrkA immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor. Mol. Cell. Biol. 20:2000;5908-5916
2. Arevalo J.C., Conde B., Hempstead B.I., Chao M.V., Martin-Zanca D., Perez P. A novel mutation within the extracellular domain of TrkA causes constitutive receptor activation. Oncogene. 20:2001;1229-1234
3. Azar C.G., Scavarda N.J., Reynolds C.P., Brodeur G.M. Multiple defects of the nerve growth factor receptor in human neuroblastomas. Cell Growth Differ. 1:1990;421-428
4. Barakat M.T., Meeran K., Bloom S.R. Neuroendocrine tumours. Endocr. Relat. Cancer. 11:2004;1-8
5. Barker P.A., Lomen-Hoerth C., Gensch E.M., Meakin S.O., Glass D.J., Shooter E.M. Tissue specific alternative splicing generates two isoforms of the TrkA receptor. J. Biol. Chem. 268:1993;15150-15157
6. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2:2000;737-744
7. Bibel M., Barde Y.-A. Neurotrophins. key regulators of cell fate and cell shape in the vertebrate nervous system Genes Dev. 14:2000;2919-2937
8. Borello M.G., Pelicci G., Arighi E., DeFilippis L., Greco A., Bongarzone I., Rizzetti M., Pelicci P.G., Pierotti M.A. The oncogenic versions of Ret and Trk tyrosine kinases bind Shc and Grb-2 adapter proteins. Oncogene. 9:1994;1661-1668
9. Butti M.G., Bongarzone I., Ferraresi G., Mondellini P., Borrello M.G., Pierotti M.A. A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas. Genomics. 28:1995;15-24
10. Coulier F., Kumar R., Ernst M., Klein R., Martin-Zanca D., Barbacid M. Human Trk oncogenes activated by point mutation, in-frame deletion, and duplication of the tyrosine kinase domain. Mol. Cell. Biol. 10:1990;4202-4210
11. Cunningham M.E., Stephens R.M., Kaplan D.R., Greene L.A. Autophosphorylation of activation loop tyrosines regulates signalling by the Trk nerve growth factor receptor. J. Biol. Chem. 272:1997;10957-10967
12. Duffey D.C., Chen Z., Dong G., Ondrey F.G., Wolf J.S., Brown K., Siebenlist U., Van Waes C. Expression of a dominant-negative mutant inhibitor-κBα of nuclear factor-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res. 59:1999;3468-3474
13. Edsjo A., Hallberg B., Fagerstrom S., Larsson C., Axelson H., Pahlman S. Differences in early and late responses between neurotrophin-stimulated trkA- and trkC-transfected SH-SY5Y neuroblastoma cells. Cell Growth Differ. 12:2001;39-50
14. Eggert A., Grotzer M.A., Ikegaki N., Liu X.G., Evans A.E., Brodeur G.M. Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. Cancer Res. 62:2002;1802-1808
15. Fakhari M., Pullirsch D., Paya K., Abraham D., Hofbauer R., Aharinejad S. Up regulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. J. Pediatr. Surg. 37:2002;1582-1587
16. Farina A.R., Tacconelli A., Vacca M., Maroder M., Gulino A., Mackay A.R. Transcriptional up-regulation of matrix metalloproteinase-9 expression during spontaneous epithelial to neuroblast phenotype conversion by SK-N-SH neuroblastoma cells, involved in enhanced invasivity, depends upon GT-box and nuclear factor κB elements. Cell Growth Differ. 10:1999;353-367
17. Franke T.F., Yang S.I., Chan T.O., Datta K., Kazlauskas A., Morrison D.K., Kaplan D.R., Tsichlis P.N. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell. 81:1995;727-736
18. George D.J., Suzuki H., Bova S.G., Isaacs J.T. Mutational analysis of the TrkA gene in prostate cancer. Prostate. 36:1998;172-180
19. Giannini G., Alesse E., Di Marcotullio L., Zazzeroni F., Gallo R., Zani M., Frati L., Screpanti I., Gulino A. EGF regulates a complex pattern of gene expression and represses smooth muscle differentiation during the neurotypic conversion of the neural-crest-derived TC-1S cell line. Exp. Cell Res. 264:2001;353-362
20. Greco A., Pierotti M.A., Bongarzone I., Pagliardi S., Lanzi C., Della Porta G. Trk-T1 is a novel oncogene formed by the fusion of TPR and Trk genes in human papillary thyroid carcinomas. Oncogene. 7:1992;237-242
21. Greco A., Mariani C., Miranda C., Lupas A., Pagliardini S., Pomati M., Pierotti M.A. The DNA rearrangement that generates the Trk-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Mol. Cell. Biol. 15:1995;6118-6127
22. Greco A., Villa R., Pierotti M.A. Genomic organisation of the human NTRK1 gene. Oncogene. 13:1996;2463-2466
23. Green L.A., Kaplan D.R. Early events in neurotrophin signalling via Trk and p75 receptors. Curr. Opin. Neurobiol. 5:1995;579-587
24. Hallberg B., Ashcroft M., Loeb D.M., Kaplan D.R. Nerve growth factor induced stimulation of Ras requires Trk interaction with Shc but does not involve phosphoinositide 3-OH kinase. Oncogene. 17:1998;691-697
25. Harris A.L. Hypoxia-a key regulatory factor in tumor growth. Nat. Rev. Cancer. 2:2002;38-47
26. Hempstead B.L., Martin-Zanca D., Kaplan D.R., Parada L.F., Chao M.V. High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low affinity NGF receptor. Nature. 350:1991;678-683
27. Holden P.H., Asopa V., Robertson A.G., Clarke A.R., Tyler S., Bennett G., Brain S.D., Wilcock G.K., Allen S.J., Smith S.K., Dawbarn D. Immunoglobulin-like domains define the nerve growth factor binding site for the TrkA receptor. Nat. Biotechnol. 15:1997;668-672
28. Jaboin J., Kim C.J., Kaplan D.R., Thiele C.J. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3′-kinase pathway. Cancer Res. 62:2002;6756-6763
29. Jogi A., Ora I., Nilsson H., Lindeheim A., Makino Y., Poellinger L., Axelson H., Pahlman S. Hypoxia alters gene expression in human neuroblastoma cells toward an immature neural crest-like phenotype. Proc. Natl. Acad. Sci. USA. 99:2002;7021-7026
30. Kaplan D.R., Stephens R.M. Neurotrophin signal transduction by the Trk receptor. J. Neurobiol. 25:1994;1404-1417
31. Kaplan D.R., Martin-Zanca D., Parada L.F. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature. 350:1991;158-160
32. Klein R., Jing S., Nanduri V., O'Rourke E., Barbacid M. The trk proto-oncogene encodes a receptor for nerve growth factor. Cell. 65:1991;189-197
33. Kolch W. Meaningful relationships. the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions Biochem. J. 351:2000;289-305
34. Lavenius E., Gestblom C., Johansson I., Nanberg E., Pahlmen S. Transfection of TrkA into human neuroblastoma cells restores ability to differentiate in response to nerve growth factor. Cell Growth Differ. 6:1995;727-736
35. Lee F.S., Chao M.V. Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc. Natl. Acad. Sci. USA. 98:2001;3555-3560
36. Loeb D.M., Stephens R.M., Copeland T., Kaplan D.R., Greene L.A. A Trk nerve growth factor (NGF) receptor point mutation affecting interaction with phospholipase C-γ 1 abolishes NGF-promoted peripherin induction but not neurite outgrowth. J. Biol. Chem. 269:1994;8901-8910
37. Lucarelli E., Kaplan D., Thiele C.J. Activation of trk-A but not trk-B signal transduction pathway inhibits growth of neuroblastoma cells. Eur. J. Cancer. 33:1997;2068-2070
38. Mahadeo D., Kaplan L., Chao M.V., Hampstead B.L. High affinity nerve growth factor binding displays a faster rate of association than p140trk binding. Implications for multi-subunit polypeptide receptors. J. Biol. Chem. 259:1994;6884-6891
39. Martin-Zanca D., Hughes S.H., Barbacid M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature. 319:1986;743-748
40. Martin-Zanca D., Oskam R., Mitra G., Copeland T., Barbacid M. Molecular and biochemical characterisation of the human Trk oncogene. Mol. Cell. Biol. 9:1989;24-33
41. Matsushima H., Bogenmann E. Nerve growth factor (NGF) induces neuronal differentiation in neuroblastoma cells transfected with the NGF receptor cDNA. Mol. Cell. Biol. 10:1990;5015-5020
42. Meakin S.O., Shooter E.M. Tyrosine kinase activity coupled to the high-affinity nerve growth factor-receptor complex. Proc. Natl. Acad. Sci. USA. 88:1991;5862-5866
43. Meakin S.O., MacDonald J.I.S., Gryz E.A., Kubu C.J., Verdi J.M. The signalling adapter FRS-2 competes with Shc for binding to the nerve growth factor receptor TrkA. A model discriminating between proliferation and differentiation. J. Biol. Chem. 274:1999;9861-9870
44. Miyazaki K., Kawamoto K., Nishiyama M., Honda H., Kato Y. Identification of functional hypoxia response elements in the promoter region of the DEC1 and DEC2 genes. J. Biol. Chem. 277:2002;47014-47021
45. Moelling K., Schad K., Bosse M., Zimmermann S., Schweneker M. Regulation of Raf-Akt cross-talk. J. Biol. Chem. 277:2002;31099-31106
46. Monshipouri M., Jiang H., Lazarovici P. NGF stimulation of erk phosphorylation is impaired by a point mutation in the transmembrane domain of trkA receptor. J. Mol. Neurosci. 14:2000;69-76
47. Nakagawara A. Trk receptor tyrosine kinases. a bridge between cancer and neural development Cancer Lett. 169:2001;107-114
48. Nakagawara A., Arima M., Azar C.G., Scavarla N.J., Brodeur G.M. Inverse relationship between trk expression and N-myc amplification in human neuroblastoma. Cancer Res. 52:1992;1364-1368
49. Obermeier A., Haltre H., Wiesmuller K.H., Jung G., Schlessinger J., Ullrich A. Tyrosine 785 is a major determinant of Trk-substrate interaction. EMBO J. 12:1993;933-941. a
50. Obermeier A., Lammers R., Wiesmuller K.H., Jung G., Schlessinger J., Ullrich A. Identification of Trk binding sites for SHC and phosphatidylinositol 3-kinase and formation of a multimeric signalling complex. J. Biol. Chem. 268:1993;22963-22966. b
51. Obermeier A., Bradshaw R.A., Seedorf K., Choidas A., Schlessinger J., Ullrich A. Neuronal differentiation signals are controlled by nerve growth factor receptor/Trk binding sites for SHC and PLCγ EMBO J. 13:1994;1585-1590
52. Oppenheim R.W. Cell death during development of the nervous system. Annu. Rev. Neurosci. 14:1991;453-501
53. Oskam R., Coulier F., Ernst M., Martin-Zanca D., Barbacid M. Frequent generation of oncogenes by in vitro recombination of Trk protooncogene sequences. Proc. Natl. Acad. Sci. USA. 85:1988;2964-2968
54. Ozes O.N., Mayo L.D., Gustin J.A., Pfeffer S.R., Pfeffer L.M., Donner D.B. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 401:1999;82-85
55. Pahlman S., Hedborg F. Development of the neural crest and sympathetic nervous system. Brodeur G.M., Sawada T., Tsuchida S., Voute P.A. Neuroblastoma. 2000;9-19 Elsevier Press, Amsterdam
56. Peng X., Greene L.A., Kaplan D.R., Stephens R.M. Deletion of a conserved juxtamembrane sequence in Trk abolishes NGF-promoted neuritogenesis. Neuron. 15:1995;395-406
57. Pennacchietti S., Michieli P., Galluzo M., Mazzone M., Giordano S., Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met oncogene. Cancer Cell. 3:2003;347-361
58. Reuther G.W., Lambert Q.T., Caligiuri M.A., Der C.J. Identification and characterisation of an activating TrkA deletion mutation in acute myeloid leukemia. Mol. Cell. Biol. 20:2000;8655-8666
59. Ribatti D., Surico G., Vacca A., De Leonardis F., La Stilla G., Montaldo P.G., Rigillo N., Ponzoni M. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma. Life Sci. 68:2001;1161-1168
60. Rodriguez-Manzaneque J.C., Lane T.F., Ortega M.A., Hynes R.O., Lawler J., Iruela-Arispe M.L. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA. 98:2001;12485-12490
61. Rumpold H., Heinrich E., Untergrasser G., Hermann M., Pfister G., Plas E., Berger P. Neuroendocrine differentiation of human primary prostatic epithelial cells in vitro. Prostate. 53:2002;101-108
62. Scaruffi P., Cusano R., Dagnino M., Tonini G.P. Detection of DNA polymorphisms and point mutations of high affinity nerve growth factor receptor (TrkA) in human neuroblastoma. Int. J. Oncol. 14:1999;935-938
63. Segal R.A., Bhattacharyya A., Rua L.A., Alberta J.A., Stephens R.M., Kaplan D.R., Stiles C.D. Differential utilization of Trk autophosphorylation sites. J. Biol. Chem. 271:1996;20175-20181
64. Sugimoto T., Kuroda H., Horii Y., Moritake H., Tanaka T., Hattori S. Signal transduction pathways through Trk-A and Trk-B receptors in human neuroblastoma cells. Jpn. J. Cancer Res. 92:2001;152-160
65. Urfer R., Tsoulfas P., O'Conell L., Shelton D., Parada L.F., Presta L.G. An immunoglobulin-like domain determines the specificity of neurotrophin receptors. EMBO J. 14:1995;2795-2805
66. Watson F.L., Porcionatto M.A., Bhattacharyya A., Stiles C., Segal R.A. TrkA glycosylation regulates localisation and activity. J. Neurobiol. 39:1999;323-336
67. Weier H.-U.G., Rhein A.P., Shadravan F., Collins C., Polikoff D. Rapid physical mapping of the human protooncogene (NTRK1) to human chromosome 1q21-q22 by P1 clone selection, fluorescence in situ hybridisation (FISH), and computer-assisted microscopy. Genomics. 26:1995;390-393
68. Windisch J.M., Marksteiner R., Schneider R. Nerve growth factor binding site on TrkA mapped to a single 24-amino acid rich leucine-rich motif. J. Biol. Chem. 270:1995;28133-28136
69. Yang Q.W., Liu S., Tian Y., Salwen H.R., Chlenski A., Weinstein J., Cohn S.L. Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res. 63:2003;6299-6310
70. Yao R., Cooper G.M. Requirement for phosphoinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science. 267:1995;2003-2005